Patients with type 2 diabetes continue to have a high residual risk for cardiovascular events despite intensive risk factor modification. Recent clinical trials have shown that the antihyperglycemic agents empagliflozin and liraglutide reduce cardiovascular events. Other drugs have been shown to have cardiovascular safety. With glucose-lowering agents proven to reduce adverse cardiovascular outcomes, many cardiologists have begun to prescribe or recommend glucose-lowering agents. Other cardiologists are not yet comfortable with this role because they are not accustomed to initiating these drugs. This document provides updated details of glucose-lowering agents associated with either proven cardiovascular benefit or safety, to help cardiologists to safely prescribe and monitor their patients with diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cjca.2017.04.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of empagliflozin on weight in patients with prediabetes and diabetes.
Sci Rep
January 2025
Health Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
The impact of blood glucose-lowering medications on weight has always been a topic of interest in the treatment of diabetic patients. This study investigates the effect of empagliflozin on weight in patients with prediabetes and type 2 diabetes. This quasi-experimental study was performed on patients with prediabetes or type 2 diabetes with an HbA1c level up to 1% higher than the treatment target, and not using other blood glucose-lowering medications.
View Article and Find Full Text PDFDapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production.
Ren Fail
December 2025
Department of Endocrinology, East Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
Background: Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease. Sodium-glucose cotransporter protein 2 inhibitors (SGLT2i) are antihyperglycemic agents that provide additional renal-protective effects in patients with DKD, independent of their glucose-lowering effects. However, the underlying mechanism remains unclear.
View Article and Find Full Text PDFArticle Synopsis
- Type 2 diabetes mellitus (T2DM) is a chronic condition marked by high blood sugar levels and insulin resistance, making effective management crucial to lowering health risks.
- A systematic review evaluated four primary treatments: SGLT2 inhibitors, DPP-4 inhibitors, metformin, and insulin, focusing on their effectiveness, safety, and long-term benefits based on recent randomized controlled trials.
- SGLT2 inhibitors showed additional cardiovascular and kidney benefits, while metformin remains a key first-line option. The review stresses the need for personalized treatment plans and suggests future research should explore direct comparisons and therapy sequences for better guidelines.
Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
Endocrinol Diabetes Metab
January 2025
Department of Hematology, Affiliated Hospital of Qingdao University, Qingdao, China.
Background: With the elevated level of NAFLD prevalence, the incidence of diabetes, hypertension, metabolic syndrome and other diseases is also significantly elevated. GLP-1RA can exert weight loss, glucose-lowering effects and various nonglycaemic effects. However, the relationship between quantitative reduction in hepatic fat content and improvement of pancreatic islet function by GLP-1RA is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!